Some patients report improvement in depressive symptoms within hours to days, while others notice changes more gradually over several weeks. Response to Spravato® varies based on individual factors, diagnosis, and treatment history. Most patients require multiple sessions to fully assess effectiveness.

Each Spravato® treatment visit typically lasts 2 to 3 hours. This includes:

• Pre-treatment assessment

• Administration of Spravato® nasal spray

• Mandatory 2-hour monitoring period required by the FDA and the Spravato® REMS program

No. Patients cannot drive or operate machinery on the day of Spravato® treatment. You must arrange safe transportation home after each session due to potential side effects such as sedation or dissociation.

Spravato® has abuse and misuse potential, which is why it is strictly regulated and only available through certified clinics under the Spravato® REMS program. When administered appropriately in a medical setting, the risk is carefully managed through screening and monitoring.

Spravato® and ketamine are related but not the same:

• Spravato® is FDA-approved esketamine nasal spray for depression

• Ketamine infusions are typically off-label for mental health conditions

• Spravato® is delivered under strict REMS safety requirements

• Insurance coverage is more common with Spravato® while ketamine infusions are typically not covered by insurance
  

Your provider can help determine which option may be appropriate for you.

Spravato® may be used with or without an oral antidepressant, depending on your diagnosis and clinical needs. Your provider will create an individualized treatment plan based on FDA guidelines, safety considerations, and your treatment history.

Spravato® is FDA-approved, but it carries important safety warnings. Potential side effects may include:

• Dissociation

• Sedation

• Increased blood pressure

• Nausea or dizziness

Because of these risks, Spravato® is only administered in a certified medical setting with monitoring. Careful screening helps determine whether Spravato® is appropriate for you.

Spravato® may not be appropriate for individuals with:

• Certain cardiovascular conditions

• A history of aneurysms or intracerebral hemorrhage

• Uncontrolled hypertension

• Certain substance use disorders

• Other medical or psychiatric conditions that increase risk

A comprehensive consultation is required to determine eligibility.

Spravato® is FDA-approved for:

• Treatment-resistant depression (TRD) in adults

• Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal thoughts or behaviors, when clinically appropriate

It is not approved for anxiety, bipolar depression, or PTSD alone.

Spravato® is a nasal spray that patients self-administer under medical supervision in a certified clinic. It is not taken at home and cannot be filled at a retail pharmacy.

The number of treatments varies by patient. Many treatment plans include:

• An initial induction phase (often twice weekly for 4 weeks)

• A maintenance phase (weekly or every other week)

Your provider will adjust frequency based on response and safety.

Many insurance plans do cover Spravato®, though prior authorization is usually required. Coverage depends on diagnosis, prior medication trials, and your specific plan benefits.

Our team can help:

• Verify insurance coverage

• Navigate prior authorization

• Explain potential out-of-pocket costs

Out-of-pocket costs for Spravato® vary depending on insurance coverage, deductibles, and visit frequency. During your consultation, we’ll review expected costs and insurance considerations before starting treatment.

Spravato® is not a cure, but it may help reduce symptoms in individuals with treatment-resistant depression. Results vary, and Spravato® is typically part of a broader mental health treatment plan.

Spravato® is FDA-approved for depressive symptoms in adults with acute suicidal thoughts or behaviors, when used as part of a comprehensive treatment plan and medical supervision. Immediate safety concerns should always be addressed urgently.

Alevea Mental Health provides Spravato® treatment in Tempe and Uptown Phoenix, AZ, serving patients throughout the Phoenix metro area, including Scottsdale, Mesa, Chandler, and surrounding communities.

Getting started begins with a Spravato® consultation, where we:

• Review your treatment history

• Assess eligibility and safety

• Discuss expectations, scheduling, and insurance
  

👉 Schedule a Spravato Consultation or

📞 Call/Text 480-923-6200

Alevea Mental Health provides Spravato® treatment in Tempe, AZ, serving patients throughout the Phoenix metro area, including Phoenix, Scottsdale, Mesa, Chandler, Gilbert, Ahwatukee, and surrounding communities.